The estimated Net Worth of Adam J. Townsend is at least $4.71 Million dollars as of 12 February 2024. Mr Townsend owns over 1,148 units of Apellis Pharmaceuticals Inc stock worth over $3,546,497 and over the last 5 years he sold APLS stock worth over $507,076. In addition, he makes $657,288 as Chief Commercial Officer at Apellis Pharmaceuticals Inc.
Mr has made over 19 trades of the Apellis Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,148 units of APLS stock worth $77,800 on 12 February 2024.
The largest trade he's ever made was exercising 110,000 units of Apellis Pharmaceuticals Inc stock on 1 December 2023 worth over $1,659,900. On average, Mr trades about 7,007 units every 22 days since 2020. As of 12 February 2024 he still owns at least 92,453 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mr Townsend stock trades at the bottom of the page.
Adam J. Townsend is the Chief Commercial Officer at Apellis Pharmaceuticals Inc.
As the Chief Commercial Officer of Apellis Pharmaceuticals Inc, the total compensation of Mr Townsend at Apellis Pharmaceuticals Inc is $657,288. There are 9 executives at Apellis Pharmaceuticals Inc getting paid more, with Cedric Francois having the highest compensation of $4,267,180.
Mr Townsend is 44, he's been the Chief Commercial Officer of Apellis Pharmaceuticals Inc since . There are 21 older and 2 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
Adam's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: